Page last updated: 2024-10-30

metformin and CKD-MBD

metformin has been researched along with CKD-MBD in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Metformin-treated rats did not develop hyperphosphatemia or hypocalcemia and this prevented the development of vascular calcification and inhibited the progression toward high bone turnover disease."1.48Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. ( Brand, K; D'Haese, PC; De Broe, ME; De Maré, A; Gottwald-Hostalek, U; Kamel, S; Lalau, JD; Neven, E; Opdebeeck, B; Verhulst, A; Vervaet, B, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Neven, E1
Vervaet, B1
Brand, K1
Gottwald-Hostalek, U1
Opdebeeck, B1
De Maré, A1
Verhulst, A1
Lalau, JD1
Kamel, S1
De Broe, ME1
D'Haese, PC1

Other Studies

1 other study available for metformin and CKD-MBD

ArticleYear
Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
    Kidney international, 2018, Volume: 94, Issue:1

    Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Humans;

2018